Our advanced science, patented technologies, and innovative approach to drug discovery and development has allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.
U.S. FDA approved as a subcutaneous injection
CINVANTI® for CINV:
U.S. FDA approved as both a 30-minute intravenous (IV) infusion and a 2-minute IV injection
ZYNRELEF® for Postoperative Pain Management:
- Approved in the U.S., Canada and 31 European Countries
HTX-019 for Postoperative Nausea and Vomiting (PONV):
- Bioequivalence of HTX-019 as a 30-second IV injection demonstrated to approved oral dose of aprepitant for PONV
- The NDA for HTX-019 for PONV was submitted in November 2021 and the FDA set a Prescription Drug User Fee Act goal date of September 17, 2022
HTX-034 for Postoperative Pain Management
Phase 2 clinical study ongoing for postoperative pain via local application into the surgical site
Sign-Up for Email Updates
Receive news and updates on Heron’s latest innovations.